Entecavir is a prescription antiviral medicine used to treat chronic hepatitis B, a long-term infection of the liver caused by the hepatitis B virus. Doctors prescribe it for adults and for children aged 2 years and older who have active liver disease. It belongs to a group of medicines called nucleoside analogues. Entecavir lowers the amount of hepatitis B virus in the body, which helps limit further damage to the liver. It is taken by mouth once a day. The same medicine is sold under the brand name Baraclude.
Entecavir treats chronic hepatitis B, which means the virus has stayed in the body for more than six months and is still active in the liver. The label describes its use in adults who have signs that the virus is still multiplying together with raised liver enzymes or other evidence of active liver disease. It is also used in adults whose liver is badly damaged and no longer working properly, a stage called decompensated liver disease. Children aged 2 years and older may take it if their liver is still working well.
The medicine comes as tablets in two strengths and as a liquid measured with a dosing spoon, which is used for children and for adults who need a smaller dose.
Entecavir is swallowed once a day. It enters the liver cells and blocks a viral enzyme that the hepatitis B virus needs in order to copy itself. The virus then multiplies far more slowly, so inflammation in the liver often settles over months of treatment.
Treatment is usually long term, and only your doctor can decide when it might be stopped. Regular blood tests show how much virus remains and how well the liver is coping.
The label carries a serious warning about stopping suddenly. Liver inflammation can flare and become severe within months of the last dose, so the medicine is stopped only under medical supervision, with blood tests for several months afterwards. Another warning concerns lactic acidosis, a rare but life-threatening build-up of acid in the blood, and liver swelling with fat deposits.
Entecavir is not a complete answer to hepatitis B. It reduces the virus but does not clear it from the body, and it may not prevent long-term complications such as liver scarring or liver cancer. Nor does it stop the virus passing to other people. The World Health Organization notes that antiviral treatment can slow the advance of liver scarring, reduce cases of liver cancer, and improve long-term survival, and that most people who start treatment must continue it for life.
Entecavir is used to treat chronic hepatitis B, a long-term infection in which the hepatitis B virus stays in the body and keeps damaging the liver. The label describes its use in people who have evidence that the virus is still multiplying, together with other signs that the liver is affected.
Adults with active viral replication and active liver disease
Adults with decompensated liver disease
Children aged 2 years and older
Most people who take Entecavir do not have serious problems, but side effects can happen. The label groups them by how urgent they are.
Common Side Effects (Usually Mild and may lessen with continued use)
The most common effects reported with Entecavir are headache, tiredness, dizziness and nausea. The European public assessment report gives rates of about 9 in 100 for headache, 6 in 100 for tiredness, 4 in 100 for dizziness and 3 in 100 for nausea.
Serious Side Effects (Seek Urgent Medical Attention)
Take Entecavir exactly as your doctor prescribes. The points below come from the medicine's label and patient information, plus general safe-use advice.
Entecavir is a nucleoside analogue, which means it is a laboratory-made version of one of the natural building blocks the hepatitis B virus uses to build its genetic material. It is described in the label as a guanosine nucleoside analogue with selective activity against hepatitis B virus. The medicine is taken up by liver cells and changed inside them into its active form.
Once activated, Entecavir competes with the virus's own building block, deoxyguanosine triphosphate, for a place on a viral enzyme called HBV reverse transcriptase, also known as HBV DNA polymerase. In plain terms, this enzyme is the virus's copying machine. When the medicine occupies it, the virus cannot reproduce.
The label describes three separate steps that Entecavir blocks: starting the viral DNA chain, copying the first strand of viral DNA, and building the second strand. Because all three are interrupted, the virus cannot finish its genetic material, and it cannot go on to infect new liver cells.
The active form of the medicine stays inside cells for a long time, with an intracellular half-life of about 15 hours, which is why one dose a day is enough. Entecavir is only a weak inhibitor of human DNA polymerases, including the polymerase found in mitochondria, the energy-producing parts of our cells.
The label states that there are not enough data from pregnant women to judge the risk to an unborn baby. A pregnancy exposure registry collects information on outcomes, and the label cites background rates in the general population of 2.7 in 100 for major birth defects and 15 to 20 in 100 for miscarriage. Animal studies did not show harm to the developing baby at exposures similar to those used in people. The label does not instruct people taking Entecavir to use contraception. If you are pregnant, planning a pregnancy, or become pregnant during treatment, tell your doctor so the benefits and risks can be discussed.
It is not known whether Entecavir passes into human breast milk, what effect it might have on the baby, or whether it affects milk production. In rats, the medicine was found in milk. The label advises weighing the benefits of breastfeeding against the mother's need for treatment and the possible effects on the baby. Patient information from the U.S. National Library of Medicine advises not breastfeeding while taking it.
The label does not list alcohol as a specific interaction with Entecavir. Because the medicine is used to protect a liver that is already infected, ask your doctor whether you should avoid alcohol.
Dizziness and tiredness are reported side effects. Do not drive or operate machinery if you feel dizzy or unusually tired.
Entecavir leaves the body mainly through the kidneys, so kidney function matters. If creatinine clearance is below 50 mL per minute, the label advises changing the dose or how often it is taken, and using the oral solution for amounts smaller than 0.5 mg. People on haemodialysis or peritoneal dialysis follow a specific schedule, and on dialysis days the dose is given after the session. Tell your doctor about any kidney problem or dialysis.
Liver impairment does not call for a dose change. People with decompensated liver disease take a higher daily dose and may be at greater risk of lactic acidosis. In decompensated disease, the European product information states that stopping treatment is not recommended.
Entecavir is used in children aged 2 years and older who have compensated liver disease. The dose is based on body weight, and the oral solution is used for smaller children. The medicine has not been studied in children younger than 2 years.
The dose is decided by kidney function rather than by age. Because kidney function tends to fall with age, older people may need blood tests to check how well their kidneys are working before and during treatment.
The label states the following for adults:
For children aged 2 years and older, the dose is based on body weight and is usually given as the oral solution.
The label does not describe more than one dose in 24 hours. Your own dose is the one your doctor has prescribed, which may differ if your kidneys do not work normally. Never change your dose and never take an extra dose without asking your doctor first.
Experience with overdose in people is limited. In studies, single doses up to 40 mg and repeated doses up to 20 mg a day for 14 days did not cause unexpected problems. If an overdose happens, the label says the person must be watched for signs of toxicity and given standard supportive treatment as needed. A 4-hour haemodialysis session removed about 13 in 100 of a 1 mg dose, so dialysis may be used in serious cases. If you think someone has taken too much Entecavir, contact your doctor or the nearest hospital emergency department straight away, and take the pack with you.
Get emergency medical help straight away for:
Contact your doctor soon if:
Therapeutic Class
Antiviral medicine for chronic hepatitis B
Action Class
Nucleoside analogue; hepatitis B virus reverse transcriptase (DNA polymerase) inhibitor
Chemical Class
Guanosine nucleoside analogue
Habit Forming
No
Checkout Editorial Policy
Top Selling Medicines
Top Health Products
Top Selling Devices
Entecavir 0.5mg

₹2,097

₹451
MRP ₹902.1
Entecavir 1mg

₹1,024.1
MRP ₹1,248.9
Entecavir 0.5mg

₹741.3

₹451
MRP ₹902.1
Entecavir 0.5mg

₹745.5

₹451
MRP ₹902.1
Entecavir 0.5mg

₹2,015.6

₹451
MRP ₹902.1
Entecavir 0.5mg

₹2,705.8

₹451
MRP ₹902.1
Entecavir 0.5mg

₹2,705.7

₹451
MRP ₹902.1
Entecavir 0.5mg

₹777.7

₹451
MRP ₹902.1
Entecavir 1mg

₹1,184.3

₹1,024.1
MRP ₹1,248.9
Entecavir 0.5mg

₹529.7

₹451
MRP ₹902.1
Entecavir 1mg

₹1,225

₹1,024.1
MRP ₹1,248.9
Entecavir 0.5mg
₹790

₹451
MRP ₹902.1
Entecavir 0.5mg

₹2,705.7

₹451
MRP ₹902.1
Entecavir 0.5mg

₹2,275

₹451
MRP ₹902.1
Entecavir 0.5mg

₹451
MRP ₹902.1
Entecavir 0.5mg

₹599

₹451
MRP ₹902.1
Entecavir 1mg

₹226.5

₹1,024.1
MRP ₹1,248.9
Entecavir 0.5mg

₹140.6

₹451
MRP ₹902.1
Entecavir 1mg

₹57.1

₹1,024.1
MRP ₹1,248.9
Entecavir 0.5mg

₹777

₹451
MRP ₹902.1
Entecavir 0.5mg

₹721.9

₹451
MRP ₹902.1
Entecavir 0.5mg

₹1,968

₹451
MRP ₹902.1
Entecavir 0.5mg

₹1,781.3

₹451
MRP ₹902.1
Entecavir 0.5mg

₹2,100

₹451
MRP ₹902.1
Entecavir 0.5mg

₹40.3

₹451
MRP ₹902.1